Compound sixty has a very large affinity to MDM2 (Ki < 1 nM), strong mobile activity, and a very good oral pharmacokinetic profile. Compound sixty is capable of obtaining complete and extended-lasting tumor regression in vivo and is also now in phase I medical trials for most cancers treatment. Tamoxifen https://josephh207ydi0.blogtov.com/profile